Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026679 | 0.91 | L3MBTL1 (0.34) | KCNH2KMT2AALDH1A1MEN1KIF11 | |
| SCHEMBL4024600 | 0.91 | L3MBTL1 (0.34) | KCNH2KMT2AALDH1A1MEN1KIF11 | |
| SCHEMBL4026766 | 0.90 | KIF11 (0.41) | KCNH2KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL4021821 | 0.90 | KIF11 (0.41) | KCNH2KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL4027189 | 0.89 | KCNH2 (0.35) | KCNH2KMT2AALDH1A1LMNAKIF11 | |
| SCHEMBL4020571 | 0.89 | KCNH2 (0.35) | KCNH2KMT2AALDH1A1LMNAKIF11 | |
| SCHEMBL4026061 | 0.89 | KIF11 (0.43) | KCNH2KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL4025183 | 0.89 | KIF11 (0.37) | ALDH1A1KIF11RORC | |
| SCHEMBL4019022 | 0.89 | KIF11 (0.37) | ALDH1A1KIF11RORC | |
| SCHEMBL4028852 | 0.89 | KCNH2 (0.37) | KCNH2KMT2AALDH1A1LMNAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KDM2B 3090/4885KCNH2 3099/4885KMT2A 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.